Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00CZT
|
||||
Former ID |
DNCL002000
|
||||
Drug Name |
Solanezumab
|
||||
Drug Type |
Monoclonal antibody
|
||||
Company |
Eli Lilly
|
||||
CAS Number |
CAS 955085-14-0
|
||||
Target and Pathway | |||||
Target(s) | Amyloid beta A4 protein | Target Info | Modulator | [532638] | |
KEGG Pathway | Notch signaling pathway | ||||
Alzheimer's disease | |||||
Reactome | Nuclear signaling by ERBB4 | ||||
Degradation of the extracellular matrix | |||||
Regulated proteolysis of p75NTR | |||||
NRIF signals cell death from the nucleus | |||||
Activated NOTCH1 Transmits Signal to the Nucleus | |||||
Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
EPH-ephrin mediated repulsion of cells | |||||
References | |||||
Ref 524370 | ClinicalTrials.gov (NCT01900665) Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo. U.S. National Institutes of Health. | ||||
Ref 541976 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6932). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.